Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Drilon A, et al. Among authors: ardini e. Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9. Cancer Discov. 2017. PMID: 28183697 Free PMC article. Clinical Trial.
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, Raddrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A, Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A, Martignoni M, Davite C, Galvani A, Isacchi A, Siena S. Sartore-Bianchi A, et al. Among authors: ardini e. J Natl Cancer Inst. 2015 Nov 12;108(1):djv306. doi: 10.1093/jnci/djv306. Print 2016 Jan. J Natl Cancer Inst. 2015. PMID: 26563355 Free PMC article.
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.
Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, Buonandi P, Marrapese G, Veronese S, Luo D, Hornby Z, Multani P, Murphy D, Shoemaker R, Lauricella C, Giannetta L, Maiolani M, Vanzulli A, Ardini E, Galvani A, Isacchi A, Sartore-Bianchi A, Siena S. Amatu A, et al. Among authors: ardini e. Br J Cancer. 2015 Dec 22;113(12):1730-4. doi: 10.1038/bjc.2015.401. Epub 2015 Dec 3. Br J Cancer. 2015. PMID: 26633560 Free PMC article.
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A. Ardini E, et al. Mol Cancer Ther. 2016 Apr;15(4):628-39. doi: 10.1158/1535-7163.MCT-15-0758. Epub 2016 Mar 3. Mol Cancer Ther. 2016. PMID: 26939704
Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.
Milione M, Ardini E, Christiansen J, Valtorta E, Veronese S, Bosotti R, Pellegrinelli A, Testi A, Pietrantonio F, Fucà G, Wei G, Murphy D, Siena S, Isacchi A, De Braud F. Milione M, et al. Among authors: ardini e. Oncotarget. 2017 Jul 24;8(33):55353-55360. doi: 10.18632/oncotarget.19512. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903424 Free PMC article.
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A. Ardini E, et al. Mol Oncol. 2014 Dec;8(8):1495-507. doi: 10.1016/j.molonc.2014.06.001. Epub 2014 Jun 12. Mol Oncol. 2014. PMID: 24962792 Free PMC article.
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P. Menichincheri M, et al. Among authors: ardini e. J Med Chem. 2016 Apr 14;59(7):3392-408. doi: 10.1021/acs.jmedchem.6b00064. Epub 2016 Mar 30. J Med Chem. 2016. PMID: 27003761
RET inhibition: implications in cancer therapy.
Borrello MG, Ardini E, Locati LD, Greco A, Licitra L, Pierotti MA. Borrello MG, et al. Among authors: ardini e. Expert Opin Ther Targets. 2013 Apr;17(4):403-19. doi: 10.1517/14728222.2013.758715. Epub 2013 Mar 6. Expert Opin Ther Targets. 2013. PMID: 23461584 Review.
32 results